Although patients with resected pancreatic adenocarcinoma are at high risk for disease recurrence, few biomarkers are available to inform patient outcomes.
Statistical Analysis
We evaluated the associations of driver gene alterations with DFS and OS using multivariable-adjusted Cox proportional hazards regression (eAppendix in the Supplement), calculating hazard ratios (HRs) and 95% CIs. We generated Kaplan-Meier curves, from which we calculated median survival, 2-year survival, and 5-year survival. In addition, we analyzed the association of gene alterations with pattern of first recurrence using multivariable-adjusted logistic regression, calculating odds ratios and 95% CIs. All hypothesis tests were 2-sided, and a 2-sided P < .05 indicated statistical significance.
Results
Baseline characteristics of the study population by institution are shown in eTable 1 in the Supplement and by the 4 main driver genes are presented in eTable 2 in the Supplement.Of the 356 patients studied, 191 (53.7%) were men and 165 (46.3%) were women, with a median (interquartile range [IQR] ) age of 67 (59.0-73.5) years. The median (IQR) DFS was 13.1 (7.0-27.8) months and OS was 21.0 (11.4-39.6) months, which are comparable to those in randomized trials. 5, 6 Activating KRAS mutations were observed in 328 patients (92.1%) (eTable 3 in the Supplement); KRAS mutations affecting 2 separate codons were found in 11 tumors (3.4% (Table 1) . In sensitivity analyses, we classified CDKN2A status using IHC and sequencing data (eTable 4 in the Supplement). Loss of CDKN2A expression by IHC was associated with worse DFS and OS regardless of CDKN2A molecular status (eTable 5 in the Supplement), which likely reflects the inability of NGS to detect the silencing of CDKN2A expression due to promoter methylation and reduced sensitivity for copy number loss in low-cellularity tumors.
By IHC, SMAD4 protein expression was lost in 175 patients (49.2%). Loss of SMAD4 expression was not significantly associated with DFS or OS in our patient population (Table 1) . We used our sequencing data to predict whether SMAD4 expression would be present or lost (eTable 4 in the Supplement). The molecular status of SMAD4 was not associated with DFS or OS when SMAD4 expression was lost by IHC (eTable 5 in the Supplement).
For TP53, we used IHC and molecular data to generate an integrated call of TP53 as wild-type or altered (eTable 4 in the Supplement). By this approach, TP53 was altered in 231 patients (64.9%). Altered TP53 was associated with shorter DFS (HR, 1.33; 95% CI, 1.02-1.75; P = .04) but was not associated with OS (HR, 1.18; 95% CI, 0.91-1.53; P = .23) ( Table 1) .
Twenty-four patients (6.7%) received preoperative therapy, which was not associated with the pattern of driver gene alterations (eTable 6 in the Supplement). In sensitivity analyses excluding these 24 patients, associations between driver gene alterations and patient outcomes were largely unchanged (eTable 7 in the Supplement).
We analyzed the association of combinatorial gene alterations with DFS and OS (eTable 8 in the Supplement). Compared with patients with 0 to 2 gene alterations, patients with 3 or 4 gene alterations had worse DFS (3 alterations HR, 1 Figure; eFigure 4 in the Supplement). The worst outcomes were identified in patients with both KRAS mutant tumors and CDKN2A expression loss. Five-year OS rates were 18.4% for patients with 0 to 2 gene alterations, 14.1% for patients with 3 gene alterations, and 8.2% for patients with 4 gene alterations. In our patient population, alterations in the 4 driver genes were not significantly associated with local recurrence as the first site of disease recurrence (eTable 9 in the Supplement).
Discussion
In a large, multi-institutional population of patients with resected pancreatic adenocarcinoma, patient outcomes were associated with alterations of the 4 main driver genes. Previous studies have assessed these genes and patient outcomes individually using a variety of methods and patient popula- tions and revealing inconsistent results. [7] [8] [9] [10] One study assessed all 4 driver genes among 79 patients who underwent rapid autopsy after death from pancreatic adenocarcinoma.
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Tumors were sequenced by polymerase chain reaction for KRAS, CDKN2A, and TP53, and IHC was performed for CDKN2A, SMAD4, and TP53. Although the sample size was small and included all stages of disease, patients whose tumors had 3 or 4 altered genes had worse DFS and OS than did patients whose tumors had 1 or 2 altered genes in unadjusted analysis. The primary results of the current study are confirmatory in a large, multi-institutional patient population, but multiple-hypothesis testing should be acknowledged when interpreting data across several biomarkers. Previous studies have suggested that loss of SMAD4 protein expression by IHC was associated with extensive metastatic spread, generating interest in SMAD4 staining as an informative biomarker to guide the use of radiotherapy. 12 However, a subsequent study of 127 patients with resected pancreatic cancer did not replicate these findings. 13 In our study population, SMAD4 staining was not associated with pattern of disease recurrence after surgical resection. Adjuvant treatment following surgical resection of pancreatic cancer improves patient survival, but outcomes remain suboptimal. 5 With the intent of improving cure rates, novel and more aggressive multiagent treatment programs are currently being devised and evaluated in the adjuvant setting. 6 Furthermore, increasing numbers of patients are receiving chemotherapy and radiation before surgical resection to rapidly initiate therapy against micrometastatic disease and select out those patients with early disease progression unlikely to benefit from surgery. 14 In the future, molecular assessment of pancreatic cancer may help guide the use and components of perioperative treatment programs. 15 
Conclusions
This study demonstrates that alterations in the 4 main driver genes are associated with patient outcomes in a large, multiinstitutional population of patients with resected pancreatic adenocarcinoma. Understanding the molecular events that determine patient outcomes has the potential to improve treatment approaches for patients with this aggressive malignancy. Role of the Funder/Sponsor: The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication. 
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eAppendix.

Assessment of covariates
From medical records, operative notes, and pathology reports, we collected sex, age at surgery, type of pancreatic resection, perioperative chemotherapy and radiation treatment, tumor location, tumor size, AJCC (7 th ed.) pT and pN stages, tumor grade, resection margin status, and presence of lymphovascular and perineural invasion. For patients referred to Dana-Farber/Brigham and Women's Cancer Center (DF/BWCC) after surgery elsewhere, slides were re-reviewed by DF/BWCC gastrointestinal pathologists.
Outcome measures
Disease-free survival (DFS) was defined as the time between surgery and disease recurrence. Patients alive without recurrent disease at end of follow-up and those who died without clear documentation of recurrence status were censored at date of last clinical contact. Overall survival (OS) was defined as time between date of surgery and date of death.
Statistical analyses
Multivariable-adjusted Cox proportional hazards regression models were built as follows: We first defined baseline covariates to be included within the model due to their a priori potential for confounding. These four covariates were: age (continuous variable), gender (male, female), institution (Dana-Farber/Brigham and Women's Cancer Center, University of Rochester Medical Center, Stanford Cancer Institute), and receipt of perioperative treatment (no, yes, unknown). To identify additional potential confounders, we selected covariates associated with: (1) the exposures of interest (driver gene alterations) using Fisher's exact and Wilcoxon rank-sum test with a threshold of P≤0.1, and (2) the outcome (DFS and OS) using stepwise forward selection with Cox proportional hazards regression with a threshold of P≤0.1. Using this approach, four additional covariates were identified for inclusion in multivariable-adjusted models: N stage (N0, N1/X), surgical resection margins (R0, R1/2/X), grade of differentiation (well/moderate, poor/undifferentiated/unknown), and lymphovascular invasion (absent, present, unknown). As a result, the final Cox regression models included age, gender, institution, receipt of perioperative treatment, N stage, surgical resection margins, grade of differentiation, and lymphovascular invasion. Given pre-existing data and separate hypotheses regarding driver gene alterations and patient outcomes, the four main driver genes were included in separate Cox proportional hazards models that included the above covariates. The proportionality of hazards assumption was verified by evaluating time-dependent variables of the cross-product of each driver gene status and time. We tested heterogeneity across institutions using the Q statistic and no significant heterogeneity was seen (P heterogeneity >0.05). Multivariable-adjusted logistic regression models included the same covariates as the Cox regression models above. All statistical analyses were performed using SAS software (version 9.4, SAS Institute).
Immunohistochemistry
Immunohistochemistry for CDKN2A (p16), SMAD4, and TP53 was performed on 4-m-thick formalin-fixed paraffin-embedded (FFPE) whole tissue sections following antigen retrieval (heated for 17 minutes in citrate buffer, pH 6.0, BioGenex Laboratories, San Ramen, California, USA) using the following anti-human mouse monoclonal antibodies: CDKN2A (clone E6H4, ready-to-use; Roche mtm laboratories AG, Heidelberg, Germany), SMAD4 (clone B-8, diluted 1:100; Santa Cruz Biotechnology, Santa Cruz, CA), and TP53 (clone DO-1, diluted 1:100; Calbiochem, MA, USA). The primary antibodies were visualized using the EnVision+ System-HRP (Dako), with a 30 minute diaminobenzidine incubation, and counterstained with hematoxylin.
Cases were assigned a classification for immunohistochemical (IHC) expression pattern only if the non-neoplastic tissue elements present in each section showed the appropriate expression pattern for each protein. If the IHC expression pattern for a case still could not be classified after repeat staining, the case was left unclassified (N=5 for CDKN2A, N=1 for SMAD4, N=11 for TP53), and the final gene call was made from the sequencing data. No cases were missing IHC and sequencing data. For CDKN2A, cases were classified as "intact/retained" if there was nuclear and/or cytoplasmic expression anywhere within the tumor or "lost" if there was complete lack of expression in the tumor. For SMAD4, cases were classified as "intact/retained" if there was nuclear expression anywhere within the tumor or "lost" if there was complete lack of expression in the tumor. For TP53, cases that showed weak, heterogeneous nuclear staining were classified as "wild-type", cases that showed strong, homogeneous nuclear staining were classified as "altered (strong, diffuse)", and cases that showed a complete absence of nuclear expression were classified as "altered (lost)".
All slides were initially classified by a researcher with expertise in pancreatic pathology (Z.R.Q.). Half of the total slides for each gene, including all cases with discordance between the initial IHC classification and the NGS-based classification were additionally reviewed by two gastrointestinal pathologists (J.A.N. and J.L.H.) who jointly assigned a final consensus IHC classification.
Targeted sequencing library construction
To study genes known or suspected to play a role in the biology of pancreatic adenocarcinoma, we built a customized, massively parallel sequencing panel that enabled us to obtain a higher depth of coverage than that typically provided by whole exome sequencing. Similar to previous work in the Dana-Farber Cancer Institute (DFCI) Center for Cancer Genome Discovery (CCGD), 1-3 two custom-designed target enrichment bait sets were designed to capture the full coding regions of either 422 (PancPanel 1) or 428 (PancPanel 2) genes, plus selected introns for 8 (PancPanel 1) or 4 (PancPanel 2) genes to facilitate detection of structural variants. PancPanel 1 was designed by including the commonly mutated genes identified in prior sequencing efforts in pancreatic cancer [4] [5] [6] as well as sequencing data from internal studies. In addition, we included genes deemed to be of exceptional biological importance, genes deemed potentially targetable with FDA-approved or experimental drugs, and genes in selected pathways thought most relevant to pancreatic cancer biology, including DNA repair, TGF-pathway, axon guidance, chromatin modification, FGF pathway, and MAPK/PI3K. After sequencing the first 122 samples using PancPanel 1, we modified the gene panel to account for emerging data and to remove genes that were not commonly altered in our tumor set. To generate PancPanel 2, we removed 35 genes from PancPanel 1and added 40 new genes. Both versions of the PancPanel included the four pancreatic cancer driver genes. For the current study, a total of 122 tumor samples were analyzed with PancPanel 1 and the remaining 257 tumor samples were analyzed with PancPanel 2.
Tissue collection, macrodissection, DNA extraction, and DNA quality control DNA was extracted from FFPE sections using the QIAamp DNA FFPE Tissue Kit (Qiagen). DNA yield was evaluated using the Quant-iT Pico Green dsDNAassay Kit (Invitrogen). A total of 320 tumor/normal pairs and 36 tumor-only cases met quality control cut-offs (>= 200 ng of gDNA based on PicoGreen) and proceeded to library construction, capture, and sequencing. DNA was fragmented (Covaris ultrasonication) to an average length of 250 bp and purified using Agencourt AMPure XP beads. Size-selected DNA was then ligated to specific adaptors during library preparation (SPRIworks, Beckman-Coulter). Based on either Bioanalyzer or TapeStation assessment (Agilent Technologies, Inc.), the fragment size distribution after fragmentation and library construction was in the expected range for the majority of samples. Each library was constructed with sample-specific barcodes and quantified using qPCR or MiSeq analysis. Seven or eight libraries were pooled in equal mass to a total of 500 ng for target enrichment using the Agilent SureSelect hybrid capture kit (Agilent Technologies, Inc.). Captured DNA was sequenced on an Illumina HiSeq 2500 (Illumina, Inc.) in rapid run mode or on an Illumina HiSeq 3000. These DNA quantification, library preparation, hybrid capture and sequencing methods were derived from those used for other gene panels developed in our genomics facility and methods used for clinical massively parallel sequencing at the Dana-Farber/Brigham and Women's Cancer Center.
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KRAS pyrosequencing
Polymerase chain reaction (PCR) and pyrosequencing were performed to evaluate the status of KRAS codons 12, 13, 61 and 146, as previously described. 7, 8 The PCR primers for amplifying KRAS codons 12 and 13 were: 5'-NNN GGC CTG CTG AAA ATG ACT GAA -3' (forward) and 5'-(Bio TEG) TTA GCT GTA TCG TCA AGG CAC TCT-3'(reverse). The sequencing primers were PF1: 5 -TGT GGT AGT TGG AGC TG-3 and PF2: 5 -TGT GGT AGT TGG AGC T-3 . The PCR primers for amplifying KRAS codon 61 were: 5 -biotin-TGGAGAAACCTGTCTCTTGGATAT-3 (forward), and 5 -TACTGGTCCCTCATTGCACTGTA-3 (reverse), and those for KRAS codon 146 were 5 -ATGGAATTCCTTTTATTGAAACATC-3 (forward), and 5 -biotin-TTGCAGAAAACAGATCTGTATTTAT-3 (reverse). The sequencing primers were 5 -TCATTGCACTGTACTCCTC-3 (codon 61), and 5 -AATTCCTTTTATTGAAACATCA-3 (codon 146). Nucleotide dispensation order for each sequencing reaction was set to maximize the number of possible mutations that can be detected. All samples were run in duplicate. 7, 8 KRAS mutant fraction by pyrosequencing was calculated using nucleotide peak heights, as measuring on the pyrogram, according to the following formula: mutant nucleotide peak height / (mutant nucleotide peak height + wild-type nucleotide peak height).
Mutation and CNV analysis by next generation sequencing (NGS)
Pooled sample reads were deconvoluted and sorted using Picard tools (http://broadinstitute.github.io/picard/picard-metric-definitions.html). Reads were then aligned to the b37 edition of the human genome reference sequence (Human Genome Reference Consortium) using bwa (http://bio-bwa.sourceforge.net/bwa.shtml) with the following parameters "-q 5 -l 32 -k 2 -o 1". Duplicate reads were identified and removed using Picard tools. 9 Alignments were further refined using GATK for localized realignment around sites of small insertions and deletions (https://www.broadinstitute.org/gatk/gatkdocs/org_broadinstitute_gatk_tools_walkers_indels_In delRealigner.php). Base quality score recalibration was also performed using GATK (http://gatkforums.broadinstitute.org/discussion/44/base-quality-score-recalibration-bqsr).
Single nucleotide variants (SNVs) were detected using MuTect v1.1.4. All samples, both tumor and normal, were run in MuTect in paired mode using a CEPH reference DNA sample as the project normal (tumor paired with CEPH, and normal paired with CEPH). For paired tumor/normal samples, all variants detected in the normal sample were then filtered out of the tumor sample variant list. Consecutive variants in the same codon were re-annotated to maximize the effect on the codon and marked as "Phased" variants. Small insertions and deletions were detected using the Indelocator tool that is part of GATK (http://www.broadinstitute.org/cancer/cga/indelocator). Variant Effect Predictor 10 was used to annotate detected variants with their predicted functional significance. In addition, each variant was annotated with its population frequency using the 6,500 exome release of the Exome Sequencing Project (ESP) database and with whether it had had been reported in the COSMIC or dbSNP databases.
Fingerprinting
Fingerprinting analysis was performed using 44 polymorphic loci to identify if the pairing strategy was performed appropriately, or if there were any inappropriate matches (e.g., tumors from different individuals matching). Picard Tools GenotypeConcordance was used to calculate the concordance of these polymorphic loci between two samples. This was performed on all pairwise combinations of samples in the cohort. The output of the pairwise comparisons was then mapped to a concordance matrix, where concordance values four standard deviations above the median concordance value for the cohort indicated a high likelihood that the samples match. Samples can match for reasons other than being from the same individual; therefore, potential matches were manually reviewed.
Required sequence coverage depths for NGS
Sequencing coverage goals were set based on the estimated tumor content of each sample. For KRAS mutant tumors, the KRAS mutant allele fraction, as estimated by KRAS pyrosequencing, was used to determine the coverage goals. For KRAS wild-type tumors, the estimated tumor content was determined by H&E morphologic review and then divided by two to produce a scaled value expected to be equivalent to KRAS mutant allele fraction, given that most tumors are heterozygous for activating KRAS mutations. All cases were then assigned one of three coverage goals: 1.) If the KRAS mutant allele fraction was < 0.10, then the tumor was assigned a coverage goal of ≥ 80% of targeted bases with > 100X coverage. 2.) If the KRAS mutant allele fraction was 0.10-0.19, then the tumor was assigned a coverage goal of ≥ 80% of targeted bases with > 50X coverage 3.) If the KRAS mutant allele fraction was ≥ 0.20, then the tumor was assigned a coverage goal of ≥ 80% of targeted bases with > 30X coverage. If the predefined coverage goal was not met for a tumor, then NGS data were considered not available for that tumor. As described in eFigure 2, 308 (87%) of tumors met the predefined coverage goals. For those tumors without available NGS data, KRAS mutation calls were made using pyrosequencing data, and CDKN2A, SMAD4, and TP53 calls were made using IHC data. No tumors were missing both NGS and pryosequencing data for KRAS or NGS and IHC data for CDKN2A, SMAD4, and TP53. Therefore, the status of all four driver genes could be assigned to all 356 tumors included in the study.
Naïve caller for KRAS mutations
To ensure maximum sensitivity for common KRAS mutations, an additional variant calling method, termed the "naïve caller" was employed at hotspot KRAS codons. After using MuTect's normal short read preprocessing step to remove common alignment artifacts, reads covering KRAS codons 12, 13, 61, and 146 were evaluated for evidence of missense mutations by running MuTect with the "forced allele" and "force output" options at the specific sites of interest. 11 If three or more reads at any codon contained the same variant, the sample was classified as positive for that specific KRAS mutation.
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Criteria for undercovered and contaminated normals Normal samples were considered to have insufficient depth of sequencing coverage if < 80% of target bases were covered at > 20X. In addition, a normal sample was considered to be contaminated with tumor cells if the naïve caller detected a KRAS variant in the normal sample that was also present in the paired tumor sample. When the matching normal was undercovered, we used both the undercovered matched normal and the ESP germline allele frequency data to filter the tumor variant calls. When the matching normal was contaminated, the tumor variant calls were filtered using only the ESP germline data.
Copy number analysis
Copy number variants were identified using RobustCNV, a somatic copy number analysis algorithm developed at DFCI CCGD. RobustCNV relies on localized changes in the mapping depth of sequenced reads to identify changes in copy number at the loci sampled during targeted capture. This strategy includes a normalization step in which systematic bias in mapping depth is reduced or removed using robust regression to fit the observed tumor mapping depth against a panel of normals (PON) sampled using the same hybrid capture bait set. Observed values are then normalized against predicted values and expressed as log2 ratios. A second normalization step is then performed to remove GC bias using a LOESS fit. Finally, log2 ratios are centered on segments determined to be diploid based on the allele fraction of heterozygous SNPs in the targeted panel.
Normalized coverage data is next segmented using Circular Binary Segmentation 12 with the DNAcopy Bioconductor package. Finally, segments are assigned gain, loss, or normal-copy calls using a cutoff derived from the within-segment standard deviation of post-normalized mapping depths and a tuning parameter, which was set based on comparisons to array-CGH calls in separate validation experiments.
Classification of functional status by sequencing data
Cases that met the predefined coverage goals were evaluated for DNA alterations in the four pancreatic cancer driver genes. For analysis of single nucleotide variants (SNVs) and small insertions and deletions, the best protein effect, as provided by Variant Effect Predictor, was used to classify variant impact. Variants that occurred in splice sites or splice regions were additionally evaluated using the splicing impact prediction tools provided by the Alamut Visual software package (Alamut Visual version 2.67, Interactive Biosoftware, Rouen, France). Selected variants were manually inspected using the Integrated Genomics Viewer (IGV, version 2.3, Broad Institute, Cambridge, MA) to ensure correct annotation by the bioinformatics pipeline. For KRAS, SNVs were further classified as wild-type or activating, depending on whether the variant had been previously reported to result in constitutive KRAS activation. For CDKN2A and SMAD4, nonsense mutations, frameshift mutations, and mutations predicted to deleteriously impact splice sites were classified as non-functional, while missense variants were classified as functional. For TP53, nonsense mutations, frameshift mutations, and mutations predicted to deleteriously impact splice sites were also classified as non-functional. However, TP53 missense mutations were further classified as functional or non-functional according the experimental functional classification and prediction of dominant-negative activity as reported in the IARC TP53 somatic mutation database (http://www-p53.iarc.fr/). 13 If no SNVs were detected for a given gene in a case, it was assigned a functional status.
For evaluation of copy number variation (CNV), calls generated by RobustCNV were reviewed along with graphical plots of copy number signals for the chromosome on which each gene resides. Taking into account the estimated tumor fraction as determined by KRAS pyrosequencing or H&E evaluation, each gene was then assigned one of the following CNV classifications: deep deletion, shallow deletion, neutral, low amplification, or high amplification.
Integration of molecular and protein expression classification
An overall molecular status for each gene was assigned by integrating the SNV and CNV results. Genes with no SNV or CNV alterations were classified as functional. Genes with a deep deletion CNV classification were classified as non-functional regardless of SNV status. Genes with either a shallow deletion, neutral, or low amplification CNV classification were classified according to their SNV functional status. Finally, a combined, overall molecular and IHC classification was created for CDKN2A, SMAD4, and TP53. For CDKN2A and SMAD4, the overall call was derived solely from the IHC status of each case. For the small number of cases where an IHC classification could not be made (N=5 for CDKN2A, N=1 for SMAD4), the integrated molecular call was used instead, as all of these cases had available NGS data. For TP53, all cases with a non-functional integrated molecular status and cases with loss of TP53 protein expression by IHC were assigned a combined non-functional status. Cases with a wild-type TP53 expression pattern by IHC and a functional TP53 molecular classification were assigned a combined functional status. Finally, cases with a strong, homogeneous mutant pattern of TP53 expression by IHC but a functional molecular status were assigned a combined functional status. For the small number of cases where an IHC classification could not be made (N=11 for TP53), the integrated molecular call was used instead, as all of these cases had available NGS data. 
